Aggressive Tumor Growth in Drug-Resistant Prostate Cancer Driven by Enzyme The absence of a protein called PKCλ/ι in prostate cancer cells enables the enzyme EZH2 to drive aggressive growth, even with androgen receptor inhibitors present. The findings could potentially lead to new therapies. The study was led by Maria T. Diaz-Meco, PhD, and Jorge Moscat, PhD, both Homer T. Hirst III Professors of Oncology in Pathology and members of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.
